Glen Santangelo, an analyst from Jefferies, reiterated the Buy rating on Collegium Pharmaceutical (COLL – Research Report). The associated price target is $40.00.
Glen Santangelo has given his Buy rating due to a combination of factors related to Collegium Pharmaceutical’s pain portfolio and market positioning. He highlights that the market has underestimated the durability and growth potential of the company’s pain portfolio, particularly for the year 2025. Santangelo believes that the revenue projections for Nucynta are more stable than consensus estimates suggest, supported by favorable developments such as the Hikma AG agreement and a recent settlement with Teva, which delays generic competition.
Additionally, Santangelo sees potential upside in the Belbuca product line, as the anticipated generic entry in 2027 may not occur as expected due to Teva’s manufacturing and regulatory challenges. He also notes that the company’s valuation appears attractive, with a low EBITDA multiple, and sees strong cash flow and a solid balance sheet as further strengths. Overall, Santangelo’s analysis suggests that the market has not fully appreciated the company’s growth prospects, leading him to reiterate a Buy rating with a price target of $40.
Santangelo covers the Healthcare sector, focusing on stocks such as Align Tech, DENTSPLY SIRONA, and Henry Schein. According to TipRanks, Santangelo has an average return of 4.2% and a 49.33% success rate on recommended stocks.